Overview
Amorphis Pharma Development works on medicines with improved bioavailability, intended to perform their function effectively while placing less burden on the body. The company also focuses on easier administration, lower costs, and improving patients’ health and quality of life.
Financials
Revenue history (in k)
Filing timeliness
No financial statement for 2024 – the filing deadline has passed. 1 of 5 financial statements was filed late (for 2021, 76 days late).
- 2024not filed
- 202328/06/2024
- 202221/06/2023
- 202129/09/2022
- 202030/06/2021
- 201923/06/2020
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2023.
Results vs industry
Industry
Offer
- Improved generic medicines
- Innovative drug formulations
- Pharmaceutical formulation development
Website technology
- Online shop
- WooCommerce
- Website
- WordPress
- Divi
Authorized Representatives
Manner of representation
The following are authorized to submit declarations concerning the company's property rights and obligations: a) in the case of a multi-member management board, two members of the management board acting jointly, including the President of the Management Board if appointed; b) in the case of a one-person management board, a member of the management board independently.
Supervisory board
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
| 50 | $675.31 | 42.735% | |
| 17 | $229.61 | 14.5299% | |
Justyna Knapik Kowalczukage 37 | 16 | $216.10 | 13.6752% |
Marian Paluchage 58 | 16 | $216.10 | 13.6752% |
| 18 | $243.11 | 15.3846% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Was a VAT taxpayer from 2019-01-04 to 2024-07-24.
Reason for removal: Art. 96 ust. 9a pkt 1 (business activity suspended for at least 6 consecutive months)
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Nov 5, 2020 | Aid for SME access to finance — aid for start-ups | $47,747$47,747 | Fundacja Przedsiębiorczości Technologicznej | |
| Dec 19, 2018 | Aid for SME access to finance — aid for start-ups | $237.2K$237,151 | Dyrektor Narodowego Centrum Badań i Rozwoju |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Natur DayS.A. | $680,635.59 | naturday.pl | ||
| Biotriosp. z o.o. | $453,662.22 | biotrio.pl | ||
| Nature's Voicesp. z o.o. | $181,977.76 | naturesvoice.eu | ||
| Pexon Polandsp. z o.o. | $122,615.96 | pexon.pl | ||
| BIO Animalisp. z o.o. | $49,176.96 | proanimali.com | ||
| Ampliconsp. z o.o. | $48,330.99 | amplicon.pl | ||
| Xenira Pharmaceuticalssp. z o.o. | $26,670.82 | xenirapharma.com | ||
| Bioresearch PharmaS.A. | $21,432.15 | bioresearchpharma.com | ||
| Sanford Biotechsp. z o.o. | $2,586.64 | sanfordbiotech.com | ||
| Grupa FinepharmS.A. | – | finepharm.pl |
Change history
| Date | Event | |
|---|---|---|
| 2026-01-05 | Business suspended | |
| 2026-01-02 | Business resumed | |
| 2024-01-01 | Business suspended | |
| 2020-06-05 | Share capital increase (5,550.00 PLN → 5,850.00 PLN) | |
| 2020-05-04 | Share capital increase (5,000.00 PLN → 5,550.00 PLN) |
FAQ
Last updated: 2026-10-07